Homocysteine Levels and Treatment Effect in the Prospective Study of Pravastatin in the Elderly at Risk

ObjectivesTo assess the effect of preventive pravastatin treatment on coronary heart disease (CHD) morbidity and mortality in older persons at risk for cardiovascular disease (CVD), stratified according to plasma levels of homocysteine. DesignA post hoc subanalysis in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), started in 1997, which is a double-blind, randomized, placebo-controlled trial with a mean follow-up of 3.2years. SettingPrimary care setting in two of the three PROSPER study sites (Netherlands and Scotland). ParticipantsIndividuals (n=3,522, aged 70-82, 1,765 male) with a history of or risk factors for CVD were ranked in three groups depending on baseline homocysteine level, sex, and study site. InterventionPravastatin (40mg) versus placebo. MeasurementsFatal and nonfatal CHD and mortality. ResultsIn the placebo group, participants with a high homocysteine level (n=588) had a 1.8 higher risk (95% confidence interval (CI)=1.2-2.5, P=.001) of fatal and nonfatal CHD than those with a low homocysteine level (n=597). The absolute risk reduction in fatal and nonfatal CHD with pravastatin treatment was 1.6% (95% CI=-1.6 to 4.7%) in the low homocysteine group and 6.7% (95% CI=2.7-10.7%) in the high homocysteine group (difference 5.2%, 95% CI=0.11-10.3, P=.046). Therefore, the number needed to treat (NNT) with pravastatin for 3.2years for benefit related to fatal and nonfatal CHD events was 14.8 (95% CI=9.3-36.6) for high homocysteine and 64.5 (95% CI=21.4-) for low homocysteine. ConclusionIn older persons at risk of CVD, those with high homocysteine are at highest risk for fatal and nonfatal CHD. With pravastatin treatment, this group has the highest absolute risk reduction and the lowest NNT to prevent fatal and nonfatal CHD.